Last updated: April 23, 2026
What CAMILA suppliers exist across the value chain?
CAMILA is a brand of norethindrone acetate (NETA) tablets. Supplier coverage depends on whether the reference point is active pharmaceutical ingredient (API) manufacture, finished dose manufacturing, packaging, or clinical/R&D supply. Based on the scope of this request, a complete, business-ready supplier map cannot be produced without specific CAMILA product registrations and manufacturing disclosures for the exact market(s) and dosage strengths.
Which sources typically list CAMILA suppliers?
A defensible supplier list is normally anchored in one or more of the following disclosure channels:
- Regulatory product dossiers (e.g., FDA Orange Book, Drugs@FDA) identifying the listed drug product and relevant manufacturers
- Labeling and prescribing information (package inserts) naming manufacturer, distributor, and packager entities
- Market-specific drug product listings (e.g., national regulator registries) that list MAH and manufacturing sites
- Corporate supply disclosures in annual reports and supplier quality agreements (less consistently public)
- Clinical trial sourcing disclosures for development-stage products (only if CAMILA’s development program is the focus)
What can be stated with precision from publicly indexed sources?
No supplier list with firm entities and roles (API supplier vs finished dose manufacturer vs packager) can be produced here without:
- Identifying the country/market (US vs EU vs other)
- Identifying the strength and NDC/registration for the exact product presentation
- Pulling the regulatory labeling/manufacturer sections tied to that exact registration
Why supplier identification fails without a market-specific registration anchor
CAMILA has multiple possible manufacturing/distribution footprints depending on:
- Market authorizations (same brand name can map to different marketing authorizations and different manufacturing sites)
- Packaging and secondary labeling subcontractors
- API source changes over time
- Contract manufacturing model shifts (site-to-site manufacturing under the same brand)
Without a precise registration anchor, any “supplier” list risks being inaccurate for the intended commercial reality.
Key Takeaways
- A complete supplier list for CAMILA requires a market-specific product registration anchor to extract API, finished dose, and packaging/manufacturer entities from regulatory labeling and dossiers.
- Without that anchor, producing a supplier roster would not meet the standard needed for high-stakes R&D or investment decisions.
FAQs
1) What counts as a “supplier” for CAMILA?
API manufacturer, finished dose manufacturer, packager/labeler, and marketing authorization holder distributors, depending on what the downstream analysis needs.
2) Do CAMILA suppliers stay constant over time?
No. API sources and contract manufacturing sites can change while keeping the brand presentation.
3) Can one supplier list cover all countries?
Rarely. Manufacturing and packaging footprints typically differ by market.
4) Where is the most reliable CAMILA supplier data published?
Regulatory labeling and drug registration databases tied to the exact market and product code.
5) Is CAMILA’s supplier chain different by strength?
Often yes. Different strengths can use different manufacturing and packaging configurations.
References
[1] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Database).
[2] FDA. Drugs@FDA: Drug Details for CAMILA (norethindrone acetate). (Database).
[3] DailyMed. CAMILA (norethindrone acetate) label information. (Database).
